Bruker Co. (NASDAQ:BRKR - Get Free Report) CEO Frank H. Laukien purchased 100,000 shares of the stock in a transaction on Monday, November 18th. The shares were bought at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the transaction, the chief executive officer now directly owns 38,439,563 shares in the company, valued at approximately $1,927,359,688.82. The trade was a 0.26 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Bruker Trading Down 2.3 %
Shares of BRKR stock opened at $48.25 on Wednesday. The stock has a 50 day simple moving average of $62.02 and a 200 day simple moving average of $64.92. Bruker Co. has a 1 year low of $48.07 and a 1 year high of $94.86. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24. The stock has a market cap of $7.31 billion, a P/E ratio of 23.20, a price-to-earnings-growth ratio of 2.46 and a beta of 1.20.
Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The firm had revenue of $864.40 million during the quarter, compared to the consensus estimate of $866.46 million. During the same period in the prior year, the business earned $0.74 earnings per share. Bruker's quarterly revenue was up 16.4% compared to the same quarter last year. On average, research analysts predict that Bruker Co. will post 2.4 earnings per share for the current fiscal year.
Bruker Dividend Announcement
Financial Prophecy
From Porter & Company | Ad
The Magnificent 7 could be in for a world of pain…
And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock.
The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on.
It’s called The Final Frontier.
Including the name of the #1 company to buy.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Monday, December 2nd will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date of this dividend is Monday, December 2nd. Bruker's dividend payout ratio is presently 9.62%.
Hedge Funds Weigh In On Bruker
A number of institutional investors have recently modified their holdings of the business. FMR LLC grew its position in Bruker by 21.4% in the third quarter. FMR LLC now owns 14,306,122 shares of the medical research company's stock valued at $987,981,000 after acquiring an additional 2,521,904 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of Bruker by 127.8% in the 2nd quarter. Marshall Wace LLP now owns 1,389,537 shares of the medical research company's stock valued at $88,666,000 after purchasing an additional 779,549 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Bruker during the 2nd quarter valued at approximately $36,472,000. Point72 DIFC Ltd increased its position in Bruker by 4,875.9% during the 3rd quarter. Point72 DIFC Ltd now owns 470,171 shares of the medical research company's stock worth $32,470,000 after purchasing an additional 460,722 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Bruker by 1,933.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 410,234 shares of the medical research company's stock valued at $28,331,000 after purchasing an additional 390,057 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company's stock.
Analyst Ratings Changes
A number of analysts have commented on the stock. Wolfe Research cut shares of Bruker from an "outperform" rating to a "peer perform" rating in a research note on Monday, September 30th. Barclays cut their target price on shares of Bruker from $75.00 to $69.00 and set an "overweight" rating for the company in a research note on Wednesday, November 6th. Wells Fargo & Company lowered their price target on Bruker from $78.00 to $75.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 6th. TD Cowen dropped their price objective on Bruker from $72.00 to $70.00 and set a "hold" rating on the stock in a research note on Wednesday, November 6th. Finally, Citigroup decreased their target price on Bruker from $80.00 to $75.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $79.36.
View Our Latest Stock Report on BRKR
Bruker Company Profile
(
Get Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
